The exploration of “Gut redox” focuses on the intricate redox equilibrium within the gastrointestinal (GI) tract, encompassing a dynamic interplay of various reactive species and antioxidants. This equilibrium plays a pivotal role in shaping gut health by influencing the composition of the gut microbiota, affecting inflammation, regulating nutrient absorption, ensuring mucosal protection, and contributing to the overall homeostasis of the gut immune system. A disturbance in the intricate equilibrium of gut redox can lead to oxidative stress, marked by an overabundance of reactive oxygen species (ROS) and reactive nitrogen species (RNS), potentially causing damage to cellular components. Although the gut is primarily anaerobic due to oxygen consumption by bacteria, certain gut cells like epithelial and immune cells can produce ROS. Immune cells, such as macrophages and neutrophils, activate NADPH oxidase (NOX) enzymes, generating superoxide radicals to combat pathogens. Epithelial cells can also produce ROS in response to inflammation, oxidative stress, or pathogen exposure. Additionally, ROS can result from dietary metabolism and interactions between gut microbes and host cells. Despite limited oxygen, ROS production in the gut plays crucial roles in both normal physiology and gastrointestinal pathologies.

The impact of ROS-associated signaling within GI tract is intricately linked to the localized concentration of ROS, leading to diverse outcomes. The various ROS, including hydrogen peroxide (H₂O₂), superoxide (O2^•-), hydroxyl radical (OH^•), and singlet oxygen, are generated through diverse intracellular pathways, with changes in oxygen partial pressure playing a significant role in creating distinct redox potentials throughout the GI tract (1, 2). Mitochondria is the primary source of ROS, generate superoxide as a byproduct of electron transport chain (ETC) activity. In this process, leaked electrons partially reduce oxygen (O₂) to produce radicals such as O2^•- or H₂O₂. The accumulation of intracellular H₂O₂ induces the Fenton reaction, leading to the formation of highly reactive hydroxyl radicals (OH^•) and posing a risk of cell and tissue damage (3–5). Excessive H₂O₂ can initiate uncontrollable chain reactions, triggering inflammatory responses (3, 6, 7).

Apart from mitochondria, membrane-bound NOX are significant ROS generators, specifically crucial for immune cell functions ( Figure 1 ). NOX1 and DUOX2, prevalent along the GI tract, produce substantial ROS quantities, essential for an oxidative burst employed by innate immune cells to eliminate phagocytized pathogens (8, 9). Additional enzymes in various cellular compartments, such as cyclooxygenases, lipoxygenases, and cytochromes P450 contribute to ROS generation (7, 10, 11). Notably, gut bacteria, including potent ROS generators like lactobacilli, are crucial in inducing controlled levels of ROS within human epithelial cells. Lactobacillus spp. likely regulate oxidative stress by influencing ROS-forming enzymes and modulating transcription factors like Nuclear factor erythroid-2-related factor 2 (NRF-2) and NF-κB (12). Studies in various models and clinical populations suggest that Lactobacillus could alleviate symptoms of conditions such as Inflammatory Bowel Disease (IBD), cancers, and liver damage by targeting inflammation and oxidative stress pathways (13). This highlights the potential therapeutic role of Lactobacillus in managing these health conditions.

Commensal gut bacteria can alter the intracellular redox environment, influencing essential cellular processes. Microbial signals activate NOX, inducing localized ROS production that influences redox sensor proteins in cells, thus affecting their activity (6, 12, 13).

Nitric oxide (NO) is a pivotal compound with intricate roles in the functioning of the intestinal microflora and beyond. It contributes to complex signaling processes in both eukaryotic cells and among gut microorganisms ( Figure 1 ). The mammalian cells’ ability to produce NO through the enzyme Nitric oxide synthase (NOS) underscores its significance as a critical signaling molecule in the gastrointestinal tract (14). However, the potential accumulation of NO can lead to the formation of highly damaging peroxynitrite (ONOO^-), which, in turn, induces cellular damage (15). Beyond eukaryotic cells, various commensal bacteria contribute to NO production through different pathways, such as bacterial NOS (bNOS) activity and dissimilatory nitrate reduction to ammonium (DNRA) (16). The generation of RNS and ROS by pathogenic bacteria contrasts with the actions of commensal gut bacteria, which play a role in reducing harmful RNS, rendering them less reactive. Unlike pathogenic bacteria that produce RNS and ROS, commensal bacteria such as Escherichia coli, Lactobacilli, and Bifidobacteria are involved in scavenging these reactive species rather than producing them. For instance, these commensal bacteria can execute denitrification, converting nitrite (NO₂ ^-) to NO and further to nitrous oxide (N₂O). Enzymes like periplasmic and cytoplasmic nitrite reductases contribute to NO production through the reduction of nitrite (17). Lactic acid-producing bacteria generate NO through non-enzymatic reduction, while E. coli and Salmonella typhimurium employ biological pathways, utilizing nitrite reductase and nitrate reductase enzymes, respectively (16, 18). These mechanisms highlight the diverse strategies employed by gut commensal bacteria to mitigate the harmful effects of RNS and ROS in the GI tract.

The redox balance within the GI tract, mirroring other physiological systems, is a delicate equilibrium between oxidation and reduction reactions. This balance is regulated by antioxidants and antioxidative enzymes, maintaining a controlled redox equilibrium under normal physiological conditions (5). This essential equilibrium allows for controlled oxidative signaling while preventing oxidative stress and the consequential damage to macromolecules such as proteins, lipids, and DNA. The transition from redox balance to oxidative stress depends on the context, exhibiting variations among tissues and cells due to their unique cellular backgrounds and antioxidant levels (19, 20). These antioxidants (enzymatic and non-enzymatic) play critical roles in the defense system. Glutathione (GSH) and thioredoxins are potent non-enzymatic antioxidants, scavenging reactive compounds and regulating redox-sensitive transcription factors (21, 22). Enzymatic defense involves key players like superoxide dismutases (SOD1/2/3), catalase (CAT), glutathione peroxidase (GPx), and glutathione reductase (GR) (23). CAT and SODs convert reactive species like O2^•- and H₂O₂ to less harmful substances (21). On the other hand, GPx plays a vital role in the glutathione-REDOX system by converting GSH to its oxidized form GSSG, effectively reducing harmful substances such as H₂O₂ and lipid hydroperoxides. The coordinated action with glutathione disulphide reductase (GSR) ensures the recycling of oxidized glutathione, highlighting the significance of these enzymes in maintaining cellular redox balance and combating oxidative stress (21). Table 1 summarizes some common ROS, RNS, and cellular antioxidants.

The antioxidant system actively maintains the redox balance, safeguarding the GI tract from oxidative stress-induced damage (21). Maintaining a balance in the GI tract is essential for proper functioning and overall health. Alterations in both the gut GM and gut metabolites can impact the GI redox balance in diverse ways. The diverse bacterial community in the gut exerts a multifaceted role, contributing to antioxidant defense and the preservation of redox balance ( Table 2 ). Notably, specific bacterial strains produce antioxidant enzymes, and their metabolic activities yield crucial elements like hydrogen gas (H₂) and short-chain fatty acids (SCFAs). These substances play pivotal roles in mitigating oxidative stress, fortifying the gut epithelial barrier, and modulating immune responses (55–57). The gut microbiota’s profound impact on immune system development and function, along with its ability to metabolize xenobiotics and produce mucin-degrading enzymes, underscores its role in reducing oxidative stress and maintaining a protective mucus layer. Recognizing the complexity and variability of the gut microbiota among individuals is crucial, with dysbiosis potentially contributing to disruptions in redox balance, oxidative stress, and GI diseases.

Essentially, cultivating a well-balanced gut microbiota is crucial for gastrointestinal health, and this can be achieved through thoughtful dietary choices, lifestyle adjustments, and interventions like prebiotics and probiotics. Recognizing the significance of a healthy and diverse gut microbiota in sustaining a harmonious gut redox environment is fundamental for overall well-being. Through these strategies, we can support a resilient gut microbiota, reduce unnecessary inflammation, and protect against disruptions in redox balance, ultimately promoting optimal health.

Recent discoveries underscore the pivotal regulatory role of cellular redox status within the GI tract in shaping various aspects of immune function. This intricate influence extends to immune cell activation or inhibition, with outcomes often dictated by the concentration of redox factors. Oxidative stress, a consequence of imbalances in redox status, significantly impacts macromolecules, contributing to a spectrum of ailments such as inflammatory diseases, autoimmune disorder, aging, cancer, and neurodegeneration. The unique contribution of ROS as a third signaling entity, akin to proinflammatory cytokines, is a noteworthy discovery (58). Functioning alongside these cytokines, ROS acts as a crucial third signal that enhances T-cell proliferation, thereby influencing immune outcomes. This third signaling dimension, as observed in studies (59, 60), underscores the intricate orchestration required for a robust immune response. The release of ROS and RNS, whether originating from exogenous sources such as gut bacteria or mucosa-resident cells, or endogenously from chronic stimulated T-cells, plays a critical role in maintaining a delicate balance between T-cell activation and inactivation. This balance is essential for the precise regulation of immune responses, highlighting the nuanced control required for optimal immune function (9, 61) ( Figure 2 ).

The delicate equilibrium of redox status emerges as a critical determinant in orchestrating the complex interplay between the GI epithelial barrier and immune cells. This finely tuned redox balance significantly influences macrophage (M1 and M2) polarization, shaping the ensuing immune response. Elevated oxidative stress tends to promote a pro-inflammatory M1 phenotype, while a more reduced environment facilitates M2 polarization, fostering tissue repair and immune regulation (62). The profound impact of redox balance extends to dendritic cells (DC), neutrophils, natural killer (NK/iNKT) cells, and innate lymphoid cells (ILCs), all pivotal players in the intricate web of mucosal immunity. Redox signaling modulates their functions, impacting processes such as antigen presentation, microbial killing, cytotoxic activity, and maintenance of gut homeostasis. Moreover, the influence of redox balance reaches into the realm of adaptive immunity, shaping the characteristics and functionality of B and T-cells (63). The redox state of the GI environment intricately modulates the equilibrium between pro-inflammatory Th1 and anti-inflammatory Th2 responses. While oxidative stress favors Th1 responses, a more reduced state may promote Th2 responses (63). Additionally, gut redox profoundly influences the generation and function of regulatory T-cells (Tregs), crucial for maintaining immune tolerance (64) ( Figure 2 ).

The unique composition of the gut microbiome, individualized for each person, plays a pivotal role in maintaining a beneficial redox balance that suppresses inflammation. Continuous immune system activation in the intestine through direct contact with the microbiota underscores the intricate balance of pro- and anti-inflammatory mechanisms influenced by these microbial communities (5, 65). Gut commensal bacteria play a role in creating an antioxidative environment, suppressing inflammation, whereas pathogenic microbiota promote inflammation and alter the redox balance toward a pro-oxidative state (66). The anaerobic conditions in the gut are essential for maintaining homeostasis by creating an environment that supports the growth of beneficial anaerobic bacteria while inhibiting the proliferation of harmful aerobic bacteria. Anaerobic bacteria are well-adapted to the low-oxygen environment of the gut and play a vital role in various physiological processes, such as digestion, nutrient absorption, and immune regulation. By fermenting dietary fibers and other complex carbohydrates, anaerobic bacteria produce SCFAs and other metabolites that help nourish the gut epithelium, modulate T-cell responses, and maintain barrier integrity. Additionally, anaerobic bacteria contribute to gut homeostasis by consuming oxygen, which helps maintain the anaerobic conditions necessary for their survival. In contrast, dysbiosis, characterized by an imbalance in the gut microbiota composition, can disrupt this anaerobic environment. Factors such as inflammation, antibiotic use, and dietary changes can lead to dysbiosis, resulting in an overgrowth of aerobic bacteria and a decrease in beneficial anaerobic bacteria. Anaerobic probiotics, such as certain strains of Lactobacillus, Bifidobacterium, and Faecalibacterium prausnitzii have been shown to help restore gut homeostasis by replenishing beneficial bacteria and promoting an anaerobic environment (67, 68). These probiotics can scavenge oxygen and produce metabolites that support the growth of anaerobic bacteria while inhibiting the proliferation of harmful aerobic bacteria. By restoring microbial balance and enhancing gut barrier function, anaerobic probiotics can help prevent inflammation and maintain gut health. The ability of these species to augment and extend antigen-specific proliferative responses in T-cells emphasizes their crucial role in fine-tuning immune outcomes. Moreover, the intricate balance of redox status significantly influences the integrity of the epithelial barrier and its interactions with immune cells. The delicate interplay between redox balance and the adaptive immune system further extends to shaping T-cell characteristics, metabolic responses, and functionality, thus impacting the equilibrium between pro-inflammatory and anti-inflammatory responses.

The influence of ROS on T-cells is intricate, demonstrating a dual role with both positive and negative impacts, contingent on the concentration of ROS and the specific context. Controlled ROS production is pivotal for T-cell activation and immune responses, while excessive or prolonged oxidative stress can contribute to T-cell dysfunction, thereby contributing to immune-related disorders. The maintenance of Redox equilibrium emerges as a critical factor for optimal immune system functionality, with oxidative signals playing a decisive role in initiating or concluding immune responses. The interplay between the gut microbiota and ROS holds significant importance in shaping the immune system. A balanced microbiome plays a key role in preserving a stable Redox balance, while dysbiosis disrupts this equilibrium, directly influencing various facets of T-cell function. The gut microenvironment, impacted by oxidative stress, influences T-cell recruitment, activation, and effector functions. Moreover, ROS regulation contributes to the delicate balance of Th1/Th2 responses, with elevated ROS levels influencing cell counts and gene expression patterns (60).

The dynamic interplay between the gut microbiome and redox equilibrium within the GI tract constitutes a multifaceted regulatory system influencing host immune responses. This intricate relationship is characterized by a delicate balance between ROS generation and antioxidant activities orchestrated by the microbiota (63). Commensal and pathogenic bacteria play pivotal roles in modulating ROS production, impacting mitochondrial function, and activating NADPH oxidases. Moreover, the microbiome exerts direct control over T-cell activity by regulating nutrient utilization, influencing host metabolism, and modulating the production of essential vitamins and enzymes.

Diverse metabolites generated by the microbiota, such as SCFAs, ethanol, lactate, phenols, and succinate, along with the transformation of bile acids, contribute to the regulation of redox homeostasis in the gut (105). This microbial influence extends beyond metabolic pathways, encompassing degradation of proteins and carbohydrates. However, the dynamic roles of the gut microbiota are not limited to metabolic processes; they extend to vital immune regulatory functions. The microbiome efficiently limits the growth of harmful bacteria in the GI tract, sustaining a harmonized immune environment (5, 84).

The involvement of pathogenic bacteria, such as E. coli and Salmonella, introduces the complexity of hydrogen sulfide (H₂S) generation during the degradation of sulfur-containing amino acids. Excessive H₂S levels impair colonic epithelial cell functions, resulting in epithelial damage, disruption of the mucus barrier, and interference with SCFAs metabolism (106). On the contrary, commensal bacterial communities, particularly probiotics, emerge as key contributors to redox homeostasis (5, 107). Probiotics exhibit antioxidative properties through the production of antioxidizes, such as SOD and CAT, and the generation of antioxidant metabolites like folate and GSH (108, 109). These beneficial microorganisms also induce antioxidative capacities in host cells, while simultaneously dampening the activities of ROS-producing enzymes. These host gut health supporting include lactic acid bacilli, E. coli Nissle 1917, Saccharomyces boulardii, and others (108, 110). The impact of the gut microbiota extends to immune cell function and differentiation, influencing the development of CD4⁺ and CD8⁺ T-cells. Recent studies highlight the microbiome’s role as an antigen, shaping microbiota-specific T-cell development in the thymus (101, 111). The differentiation of T-cells into effector Th1, Th2, Th17, regulatory Treg cells, and cytotoxic CD8⁺ T-cells is modulated by distinct commensal microbiota, contributing to the maintenance of host immune balance ( Figure 5 ).

In addition to directly affecting the production of ROS, antioxidants, and RNS, bacteria employ various strategies to indirectly regulate the redox state and influencing T-cell homeostasis. Metabolites such as formyl-peptides, SCFAs, including butyrate, propionate, and acetate derived from gut microbial fermentation, impact the redox balance. SCFAs play a crucial role in the regulation of T-cell differentiation and function (132). These microbial metabolites impact the activation and function of CD4⁺ and CD8⁺ T-cells through mechanisms involving epigenetic modifications and immune cell signaling. CD4⁺ T-cells, enriched in intestinal tissue, play a key role in maintaining homeostatic responses. Germ-free animal studies indicate an imbalance between Th1 and Th2 immune responses, favoring a Th2 type of immune response. The metabolic reprogramming of naïve CD4⁺ T-cells leads to the development of unique subsets, such as Th17 and Treg cells, which play a role in managing pathologies that can harm the host (133). Formylated peptides derived from commensals bind to G protein receptors (GPR) on immune cells, including macrophages, neutrophils, and epithelial cells, triggering inflammatory processes and increasing ROS generation in the gut through the activation of NADPH oxidases (5, 134) ( Figure 6 ). Additionally, certain bacteria like Lactobacilli, Bifidobacteria, Streptococcus, and Bacilli have the capability to synthesize NO (17, 135). These SCFAs play diverse roles in T-cell regulation in addition to serving as an energy source for epithelial cells influencing neuronal development and various physiological functions of organs through systemic circulation (5).

The regulatory actions of SCFAs rely on specific receptors expressed in various cell types. Research indicates that free fatty acid receptors (FFARs) play a role in regulating metabolic energy and influencing the immune system (136). Butyrate’s interaction with the FFAR receptor modifies the AMP/ATP ratio, activating AMP-activated protein kinase (AMPK). This activated AMPK facilitates the translocation of Nrf-2 into the nucleus. Nrf-2, a pivotal transcription factor, controls over 200 genes involved in cellular antioxidant defense (137) ( Figure 6 ). In the nucleus, Nrf-2 binds with antioxidant response element (ARE) to activate the antioxidant defense system. Moreover, SCFAs activate FFARs, initiating the RAS/RAF/MEK/ERK signaling pathway, leading to proliferation (136). Additionally, inhibiting Histone deacetylases (HDACs) enhances the synthesis of Nrf-2, thus activating oxidative defense mechanisms. Among the SCFAs, butyrate stands out as the most potent inhibitor of HDAC activities. Mechanistically, butyrate hinders the recruitment of HDACs to the promoter by transcription factors specificity protein 1 and 3 (Sp1/Sp3), resulting in histone hyperacetylation (138). Through HDAC inhibition, butyrate plays a pivotal role in suppressing cell proliferation, differentiation, and apoptosis in T-cells. It also contributes to the downregulation of proinflammatory effectors in lamina propria macrophages and regulates cytokine expression in T-cells (139). Collectively, these studies highlight epigenetic regulation, involving HDACs and/or Nrf-2 nuclear translocation, as the main reported mechanisms of action for butyrate. By strengthening antioxidant defenses, SCFAs mitigate ROS mediated mitochondrial damage and enhance mitochondrial function. This protective action not only safeguards mitochondrial metabolism but also ensures a more efficient energy supply to the cells.

Butyrate and propionate have been reported to increase colonic FoxP3⁺ Tregs, potentially through their HDAC inhibitor activity (140–142). Clostridia induce colonic peripherally induce Treg (pTreg) cells through butyrate production, and their oral administration to mice imparts resistance to colitis and allergic diarrhea (143–145). Additionally, all major SCFAs, including acetate, propionate, and butyrate, enhance the generation of effector T-cells (Th17 and Th1) as well as IL-10⁺ CD4⁺ T-cells in both in vitro and in vivo settings (146, 147). In a mouse model study, SCFAs, specifically butyrate produced during starch fermentation by commensal microorganisms, were found to facilitate the extrathymic generation of Treg cells. The increased Treg-cell numbers induced by butyrate were attributed to the potentiation of extrathymic differentiation, dependent on the intronic enhancer CNS1 (141). Experimental studies have shown that butyrate enhances extrathymic differentiation of Treg cells. These studies utilized Specific Pathogen-Free (SPF) mice lacking an intronic Foxp3 enhancer CNS1, resulting in selective impairment of extrathymic Treg cell differentiation while maintaining intact thymic differentiation. Findings of this study revealed that butyrate was unable to restore impaired Foxp3 induction in naïve CD4⁺ T cells lacking CNS1. Additionally, extracts of feces from SPF mice facilitated Foxp3 induction when peripheral naïve CD4⁺ T cells were stimulated with CD3 antibody in the presence of DCs, IL-2, and TGF-β. Furthermore, in vitro experiments demonstrated that butyrate treatment increased the number of Foxp3⁺ cells in DC-free cultures of purified naïve CD4⁺ T cells stimulated by CD3 and CD28 antibody-coated beads and TGF-β. This effect was likely attributed to enhanced Foxp3 protein acetylation induced by butyrate, a known histone deacetylase (HDAC) inhibitor (148, 149). Another SCFA, propionate, with HDAC inhibitory activity, also enhanced de novo Treg-cell generation in the periphery (141). In contrast, acetate, which lacks HDAC-inhibitory activity, did not demonstrate a similar effect (141). These observations underscore the significance of bacterial metabolites in facilitating communication between the commensal microbiota and the immune system, thereby impacting the equilibrium between pro- and anti-inflammatory mechanisms. Commensal microbe-derived butyrate has been shown to induce the differentiation of colonic regulatory T-cells and inhibit IL-17, generating Tregs to alleviate colorectal colitis in rats (149, 150). Additionally, bile acid metabolites from gut microbes promote Treg cell differentiation through the generation of mitochondrial ROS (151).

Bile acid metabolites derived from gut bacteria exhibit suppressive effects on Th17 cells and promote the activation of CXCR5⁺ CD4⁺ T follicular helper (Tfh) cells in Neuromyelitis Optica Spectrum Disorder recurrence (152). Furthermore, bile acid metabolites contribute to the differentiation of Th17 and Treg cells (151). Hang et al. recently identified two derivatives of lithocholic acid (LCA), 3-oxoLCA and isoalloLCA, as T-cell regulators ( Figure 6 ). Simultaneous administration of these derivatives decreased Th17 cell differentiation and elevated Treg cell expression in the ileum. The suppressive impact of 3-oxoLCA on Th17 cells was facilitated by RORγt inhibition, whereas isoalloLCA boosted Treg cells by increasing mitochondrial reactive oxygen species production and enhancing FOXP3⁺ expression through the intronic enhancer conserved noncoding sequence (CNS). Additionally, 3-OxoLCA strengthened the activity of isoalloLCA on Treg cells (151). This data unveils a novel mechanism through which bile acid metabolites directly modulate the balance between Th17 and Treg cells, influencing host immune responses. The primary gut microbiota species responsible for converting lithocholic acid (LCA) to 3-oxoLCA and isoLCA include Bifidobacterium, Enterocloster, Adlercreutzia, Clostridium, Collinsella, Eggerthella, Gordonibacter, Mediterraneibacte, Monoglobus, Peptoniphilus, Phocea, and Raoultibacter (153). Overall, SCFAs significantly impact regulatory T-cells and effector T-cells based on the immunological context, with intestinal T-cells being a major target due to elevated SCFAs levels in colonic tissues and gut-associated lymphoid tissues.

The GI tract, being the largest mucosal surface, faces threats from pathogens. It boasts various defense mechanisms against pathogen invasion and tumor formation, including a network of innate and adaptive immune cells. This immune response is crucial as the GI tract interacts with the gut microbiome and absorbs nutrients. Immunological memory, particularly in naïve CD8⁺ T-cells, plays a pivotal role. Upon infection, these cells rapidly expand to mount an effective defense, ensuring long-lasting immunity. Generation of memory T-cells are a critical component of the adaptive immune system that provides long-lasting immunity against previously encountered pathogens. These memory T-cells can be broadly categorized into three primary populations: central memory T-cells (TCM), effector memory T-cells (TEM), and tissue-resident memory T-cells (TRM), distinguished by their location, function, and migratory properties (154, 155). TRM cells are an integral part of the immune system’s defense strategy, persisting in various locations throughout the body demonstrating their versatility in immune surveillance and response. While they are prominently found in barrier tissues like the GI tract, skin, and lungs, they also reside in non-barrier tissues such as brain (156–158). The GI tract is constantly exposed to various commensals, pathogenic bacteria, viruses, and other potentially toxic agents. Within this environment, the balance of redox reactions, microbiota-derived compounds, and metabolites profoundly affects various aspects of the host’s physiological functions, particularly the response of TRM cells. These cells, crucial for immune defense, are in close proximity to the gut microbiota within the mucosal barrier. Environmental factors such as dietary patterns and nutritional status significantly influence the intricate relationship between the host and its gut microbiota, impacting immune responses. The signals generated from this dynamic interaction, along with the production of metabolites, and ROS likely play a pivotal role in shaping the development, maintenance, and functionality of TRM cells within the GI track.

Studies indicate the involvement of the adenosine monophosphate-activated protein kinase (AMPK)/nicotinamide adenine dinucleotide phosphate (NADPH) oxidase signaling pathway in oxidative stress and inflammatory responses (159). There is growing evidence that metabolite produced by gut microbiota plays a role in regulating AMPK activity (160). SCFAs reduced the activating enzymes like NADPH oxidases within the host cells, which are responsible for ROS generation (136) ( Figure 7 ). Accumulating evidence indicates that SCFAs mediate significant anti-inflammatory action by restricting ROS production which may prevent excessive immune response and maintaining gut epithelial barrier (161, 162). The SCFAs not only stabilize gut-resident regulatory T-cells and diminish inflammatory innate immune cells but also enhance the survival and function of CD8⁺ memory T-cells (141, 163). Gut microbiota-derived SCFAs direct T-cell metabolism toward OXPHOS and Fatty Acid Oxidation (FAO), benefiting long-term survival (164). Additionally, SCFAs influence the capacity of antigen-activated CD8⁺ T-cells to differentiate into memory CD8⁺ T-cells with enhanced recall response (165). Additionally, it is well established that SCFAs acts as a modulator for cellular redox homeostasis by inducing a signaling pathways, involving Nrf-2 a master regulator of antioxidant defense (136, 137). In normal circumstances, Nrf-2 is confined within the cytoplasm by Keap1, which acts as a substrate adapter protein, aiding in the ubiquitination and subsequent degradation of Nrf-2 through the proteasome. However, under oxidative stress conditions, Nrf2 is dissociated from Keap1 due to the thiol modification of Keap1 cysteine residues. This allows Nrf-2 to translocate into the nucleus, where it forms a heterodimer with small Maf proteins and binds to the ARE in the promoter regions of target genes. This binding activates the transcription of a wide array of genes encoding detoxifying enzymes, antioxidant proteins, and other cytoprotective factors.

Bacterial pathogens like Salmonella and E. coli can generate H₂S while breaking down sulfur-containing amino acids. Elevated levels of H₂S can disrupt cellular functions, particularly in colonic epithelial cells. Increased levels of H₂S can interfere with the proper functioning of colonic epithelial cells. H₂S can interfere with the mitochondrial electron transport chain, specifically blocking complex IV. This interference can impair cellular energy production and overall cellular health. H₂S induced disruption can affect the metabolism of SCFAs, which are crucial for gut health and various metabolic processes in the body including the long-term survival of T-cells. H₂S at heightened levels can compromise the integrity of the mucus barrier in the colon (5). The activation of REDOX-sensitive transcription factors like NF-κB and AP-1 is intricately linked to oxidative signaling pathways. When triggered, these transcription factors respond to changes in the cell’s redox environment. It has been implicated that extracellular cues at the time of pathogen challenge are crucial for cell differentiation into either T effector cells (Teff) or Treg cells. Treg cells primarily utilize FAO and OXPHOS as opposed to Teff that use aerobic glycolysis under proinflammatory conditions or increased ROS conditions. Enhanced Treg cell activity has been reported to promote TRM cell maintenance and development via TGF-β production. Additionally, TGF-β-activated kinase 1 (TAK1) is considered a key regulator of ROS in the intestinal epithelium. This study demonstrates that the deficiency of TAK1 led to a decrease in the expression of multiple antioxidant-responsive genes and diminished the protein levels of the pivotal antioxidant transcription factor Nrf-2. Studies using mouse models with genetic ablation of TAK1 have demonstrated its essential role in preventing oxidative tissue injury in the epidermis and intestinal epithelium. Deletion of TAK1 specifically in intestinal epithelial cells leads to a decrease in the protein levels of NRF-2 in the intestine. Furthermore, Tak1 deficiency results in the spontaneous upregulation of ROS in these tissues even without external stimulation, indicating that TAK1 plays a crucial role in regulating cellular antioxidant levels under steady-state conditions (166). Consequently, this deficiency resulted in the accumulation of ROS. Moreover, like Treg cells, the development and survival of TRM cells are majorly dependent on OXPHOS (167). When ROS production exceeds the capacity of the cell’s antioxidant systems it impairs OXPHOS complex and further promotes ROS production (168, 169).

A group of transmembrane proteins widely expressed on various immune cells immune cells including CD8⁺ T-cells in the gut (170). Heiss et al. were the first to propose the involvement of eATP/P2X7R in altering intestinal T-cell immunity. P2XR7 plays an important role in purinergic signaling pathway during inflammatory responses (171). At lower ATP concentrations, P2X7R functions as ion channels for Na⁺, K⁺, or Ca2⁺. However, in high ATP environments, P2X7R can create large pores, leading to heightened permeability and triggering cell apoptosis (171). Studies also indicate that when there’s a high presence of extracellular NAD⁺, P2RX7 receptors can facilitate cell death of the gut TRM cells (172). P2RX7 is known to mediate overall mitochondrial homeostasis in the event of low intermittent levels of eATP that induces cytosolic Ca2⁺ influx. Furthermore, recent research suggests that the purinergic receptor P2RX7 plays a pivotal role in the differentiation and maintenance of CD8⁺ TRM cells. Parabiosis experiments involving the conjoining of mice that had received co-adoptive transfer of WT and P2RX7^−/− P14 cells, followed by LCMV infection, along with non-transferred, infection-matched controls, indicate that P2RX7^−/− P14 cells not only exhibited deficiencies in forming TRM cells but also displayed reduced retention in the tissues. Moreover, P2RX7^−/− P14 cells in the small intestine demonstrated higher percentages of cell death at late memory time points. P2RX7 stimulates the expression of TGF-β receptors on effector T-cells, increasing their sensitivity to the cytokine TGF-β and facilitating their differentiation (173). TGF-β triggers a transcriptional program in tissue-infiltrating CD8⁺ T-cells, inducing characteristics akin to TRM cells (174). Additionally, P2RX7 enhances CD103 upregulation on CD8⁺ T-cells which is a known residency marker required interacts with E-cadherin and contributes in the establishment and maintenance of intestinal TRM cells (173, 175). Nonetheless, in patient with Crohn’s disease over expression of P2X7R in intestinal epithelium and lamina propria were found to be linked with increased proinflammatory cytokine, increased rate of apoptosis and lower levels of IL-10 (176). Interestingly, in another study it was suggested that lamina propria Treg cells showed increased rate of apoptosis suggesting impaired immunosuppressive role of Treg cells in chronic IBD (177). Interestingly, another study suggested an increased rate of apoptosis in lamina propria Treg cells, implying a compromised immunosuppressive role in chronic IBD (177). Moreover, research indicates reduced expression levels of CD8⁺CD103⁺ tissue-resident memory cells in the inflamed mucosa of IBD patients. In contrast, ^CD8+KLRG-1⁺ T-cells, which possess enhanced proliferation and cytotoxic potential, are significantly elevated in these patients (178). These findings underscore the diverse functional profiles of TRM cells within the intestinal mucosa, influencing tissue homeostasis and immunoregulation (178). Purinergic signaling influences the functioning of antioxidant enzyme systems, thereby contributing to alterations in the cellular redox potential. The P2X7 receptor plays a role in regulating the redox potential and can serve as an inducer of H₂O₂ production, facilitated by the release of Ca2⁺ (179). P2X7 inhibitors, such as polyphosphonamides and oxidized ATP, effectively hindered H₂O₂ production. Conversely, P2X7 agonists like BzATP stimulated the generation of ROS by activating NADPH oxidase in murine macrophages (180). These studies suggest a potential scenario in which elevated levels of P2X7 under inflammatory conditions, along with increased ROS, may play a role in establishing TRM cells. Furthermore, future investigations are essential to comprehend the role of P2X7R in situations characterized by imbalanced ROS.

TRM cell development and maintenance are associated with unique set of transcription factors such Bhlhe40, Blimp-1, Ahr, Runx3, Eomes, and Nur77. Bhlhe40 stands as a stress-responsive transcription factor pivotal in various cellular physiological reactions and responses (167, 181). TGF-β promotes induction of Bhlehe40 in alveolar macrophages and cancer cells (182, 183). Additionally, TAK1 serves as a pivotal regulator of ROS (184). TGF-β also plays a key role in TRM cell development and maintenance, it may be possible that TRM development may be modulated by TGF-β expression under appropriate redox level (167). Moreover, previous studies have reported that Bhlehe40 regulates the function of major organelle involved in the cellular oxidation process. The induction of SOD2 by Bhlehe40 indicates that Bhlehe40 selectively activates ROS scavenging enzymes. In simpler terms, Bhlhe40 plays a crucial role in reducing ROS levels through its mediation of ROS-reducing mechanisms, notably through the activation of SOD2 (185). Additional research is necessary to delve deeper into how Bhlhe40 precisely diminishes ROS levels in the gut. Collectively, a growing body of evidence implicates that redox status of the gut microenvironment influences various cellular activities such as cellular signaling, growth, differentiation, apoptosis, and metabolism. A dense population of memory cells in the human intestinal mucosa are resident in nature that display a distinct phenotype and transcriptional profile contributing to intestinal homeostasis and immunoregulation. These specialized cells generate a robust immune response against reinfection. In recent years, studies have demonstrated that TRM cells participate in the pathogenesis of IBD, other chronic inflammatory responses including intestinal cancer. Therefor TRM might be the potential target to enhance immunological protection.

Mucosal-associated invariant T (MAIT) cells are T-cells with an innate-like nature, featuring a semi-invariant T-cell antigen receptor (TCR) that recognizes microbial non-peptide antigens presented by MR1 (186). Restricted by MR1, MAIT cells recognize bacterial and vitamin B metabolites (187, 188), also activated by cytokines independently of TCR (189). Abundant in mucosal tissues, blood, skin, and liver, constituting 2–5% of human T-cells (190). MAIT cells exhibit potent anti-microbial responses during infections, autoimmunity, and cancers (186, 191). Upon activation, they produce granzyme B, TNF-α, IFN-γ, and IL-17A, demonstrating cytotoxicity and inflammatory responses. Additionally, MAIT cells regulate gut epithelial barrier homeostasis (192). Biologically significant markers on MAIT cells encompass the Vα7.2 TCR, co-stimulatory molecules (CD8⁺/⁻, CD4⁺/⁻, CD28), major activation markers (HLA-DR, CD69, CD39, CD38), the coinhibitory molecule LAG-3, and PD-1. Additionally, MAIT cells express various cytokine receptors (IL-12R, IL-15R, IL-18R, and IL-23R), chemokine receptors (CCR5, CCR6, CCR9, CXCR6), as well as CD161, MDR1, CD26, and the degranulation marker CD107a. The key transcription factors expressed by MAIT cells include Eomesodermin, RORγt, PLZF, and Tbet. Like unconventional NKT and γδ T-cells, MAIT cells exhibit swift cytokine responses upon activation, expressing NK-associated CD161 and NKG2D markers, typically linked to NK cells (193). This section explores the influence of ROS and RNS in the GI tract on the differential regulation, activation, and function of MAIT cells, unraveling their interactions with various immune cells in the GI tract and contemplating the prospective therapeutic applications of MAIT cells. The activation of MAIT cells occurs through TCR ligation by riboflavin intermediates presented on MR1, supported by specific cytokines or toll-like receptors (TLR), as illustrated in Figure 8 . Upon activation, these cells undergo significant expansion, triggering a swift innate-like immune response and demonstrating effector functions, including the generation of anti-microbial cytotoxic products, inflammatory chemokines, and cytokines (194). The microbiota plays a crucial role in the development and activation of MAIT cells. Gut bacteria possessing the riboflavin biosynthesis pathway, such as Lactobacillus, Salmonella, E. Coli, Staphylococcus, Mycobacteria, Shigella Flexneri, and Clostridioides species, along with riboflavin-producing fungi like Aspergillus, Candida and Saccharomyces can activate MAIT cells in an MR1-dependent manner (194). Among bacterial phyla, Bacteroidetes and Proteobacteria were high stimulators, while Actinobacteria and Firmicutes were less stimulatory. Among MAIT cells Vb2⁺ MAIT cells exhibits the highest activation profiles (195).

Upon activation, MAIT cells identify bacterial antigens, including 5-OP-RU, presented by the MHC class 1b protein MR1, resulting in the release of cytokines such as TNF-α, IFN-γ, and IL-17A (101). These MAIT cells exhibit antimicrobial functions, and infections with E. coli, Salmonella typhimurium, Francisella tularensis, Mycobacteroides abscessus, and Lactococcus lactis activate and enhance MAIT cell function (101) ( Figure 8 ). The gut relies on the presence of neutrophils to balance pathogen protection and prevent excessive inflammation. Dysregulation of neutrophil effect on MAIT cell activation (CD69, OX40) and cytokine production (TNF-α, IFN-γ) through release of H₂O₂. In an in vitro system, the study demonstrated that neutralizing H₂O₂ with catalase reversed neutrophil-induced suppression of MAIT cells (196). This insight highlights the intricate interplay between neutrophils and MAIT cells in gut immunity. In colon adenocarcinoma patients, MAIT cells play a significant role, being activated by various bacteria. A recent study by Li et al. (197) explores the impact of MAIT cells on antitumor immune responses in colon cancer, revealing insights into how the microbiota influences MAIT cell modulation. The research indicates an increase in CD39⁺ MAIT cells in colorectal cancer, activated and responsive to microbial antigens in a TCR-dependent manner (197). Notably, gut bacteria associated with CRC, particularly bacteroides and fusobacterium strains, influence MAIT cell functions. Fusobacterium nucleatum and its culture supernatants activate MAIT cells, inducing IFNγ production, dependent on TCR engagement.

The future therapeutic potential of MAIT cells, considering their modulation by ROS, holds promise for addressing infections, autoimmune conditions, and other immune-related disorders. In summary, while specific references for the direct influence of ROS on MAIT cell differentiation are not provided due to the evolving nature of research, the existing literature supports the idea that ROS likely contribute to the regulation and function of MAIT cells in the gastrointestinal tract (191). Additional research is necessary to clarify the intricate mechanisms and potential therapeutic applications. Subsequent investigations will unveil the dynamics of vitamin B2-derived metabolites in vivo, both under steady-state conditions and throughout the progression of infections and wound healing processes. Enhanced comprehension of MAIT cell triggers, coupled with the creation of stable agonists, will open avenues for harnessing the clinical potential of these plentiful T-cells.

The dysfunction of the mucosal immune response is implicated in the pathogenesis of chronic inflammation of the gastrointestinal tract such as IBD, Crohn’s disease (CD), and ulcerative colitis (UC) (198). NO plays a multifaceted and crucial role in the intestine influencing smooth muscle relaxation, blood flow regulation, maintenance of epithelial barrier, microbial defense, and importantly immune regulation (15, 199). NO can be produced in eukaryotic cells by oxidation of L-arginine by NO synthase (15). Moreover, studies provide strong evidence suggesting that colonic epithelial cells serve as the primary source of NO production and NOS activity ( Figure 9 ). This activity has been reported to be elevated in the mucosa of patients with UC (200). iNOS is essential to maintain a protective Th1/Th2 type of immune response via balanced production of proinflammatory and anti-inflammatory cytokine. However, dysregulated balance of immune response is often associated with inflammatory events.

Earlier research has indicated that the disturbance in the balance of cytokines is implicated in the initiation and advancement of IBD, CD and UC (198). iNOS is essential to maintain a balanced and protective Th1 and Th2 type of immune response and production of related cytokines (201). The elevated Th1 type of immune response is involved in the pathological process of CD (202). Accumulating evidence indicates increased production of NO following exposure to a pro-inflammatory stimulus like IFN-γ, TNF-α, IL-1β, IL-6 and microbial products like lipopolysaccharide (LPS) ( Figure 9 ). The NF-κB a key transcription factor that exerts a crucial influence in regulating the survival, activation and differentiation of innate immune cells and inflammatory T- cells. The activation of NF-κB is a complex process that includes its translocation into the nucleus, where it can regulate the expression of various genes involved in proinflammatory process, including iNOS. The translocation of NF-κB is enabled by the phosphorylation of its inhibitor, IκBα. The degradation of IκBα is initiated through its site-specific phosphorylation by the IκB kinase (IKK) complex (203, 204). iNOS is highly expressed upon activation of the transcription factor NF-κB in response to pro-inflammatory cytokine. Interestingly, studies also suggests that sulfate and glucuronide metabolites in the intestine and phenolic compounds such as hydroxytyrosol and Tryrosol can also inhibits NF-ĸB-induced iNOS gene expression by activating Nrf-2 signaling (205, 206). These metabolites and their parent compound prevent the phosphorylation of IκBα, thereby preventing the activation of NF-ĸB (207). Moreover, the intestinal concentrate of these phenolic compounds also acts as antioxidant and anti-inflammatory agent contributing to its protective role (207, 208). During mucosal inflammation, the local immune response is primarily skewed toward a Th1 type, characterized by the release of cytokines TNF-α, IL-12, and IL-18 (209–212). Additionally, experimental murine colitis models demonstrated that neutralizing antibodies against TNF-α, IL-12, or IL-18 prevent the onset of colitis which further indicate that proinflammatory immune responses predominate in inflamed mucosa (210, 213). Transcription factor T-box expressed in T cells (Tbet), a key regulator of Th1 development via induction of IFN-γ and repression of Th2 cytokine. The upregulation of Tbet correlates with the production of IFN-γ, leading to the subsequent release of IL-12 and inducing Th1-mediated immunopathology in CD (212). In line with this, abnormalities in the levels of IFN-γ and IL-12 indicate a dysregulation of intestinal immunity. Higher levels of IFN-γ and IL-12 strongly correlate with high levels of NO in sera and colonic mucosa (214). IBD involve complex interactions between various cytokines and signaling pathways, contributing to chronic intestinal inflammation. Pro-inflammatory cytokines such as TNF-α, IL-1β, and IFN-γ activate NF-κB and STAT-1 and 3 pathways, leading to the upregulation of Smad-7 expression (215, 216). Elevated Smad-7 levels inhibit TGF-β signaling, a critical anti-inflammatory pathway, observed in IBD (217). Additionally, TGF-β production effectively suppresses experimental granulomatous colitis, highlighting its protective role (218). However, TGF-β knockout mice display increased NO production and iNOS expression, suggesting its regulatory function in dampening pro-inflammatory responses, including iNOS expression ( Figure 9 ).

Conversely, an exaggerated Th2 immune response, characterized by anti-inflammatory cytokines dominance, may contribute to intestinal inflammation. Breaches in intestinal integrity trigger Th2 response, releasing IL-33, an alarmin that binds to ST-2 receptors on various immune cells. While IL-33 initially promotes wound healing, dysregulated IL-33/ST2 signaling is implicated in chronic intestinal inflammation (219, 220). Elevated IL-33 levels in IBD patients correlate with disease severity, and aberrant f-IL-33 isoform localization in intestinal epithelial cells further exacerbates inflammation. a substantial elevation of ST2 expression was also reported in the intestinal mucosa and sera from IBD patients (220). Furthermore, NO, a key mediator in mucosal damage and chronic inflammation, is regulated by cysteine oxidation. Cystine, a glutathione substrate, mitigates inflammation by preserving intestinal barrier integrity under oxidative stress. Overall, dysregulated cytokine signaling, particularly involving TGF-β and IL-33, along with NO-mediated oxidative stress, contribute significantly to the pathogenesis of IBD, highlighting potential therapeutic targets for intervention (221, 222) ( Figure 9 ).

Th17 cells, characterized by the RORγt transcription factor and IL-17 cytokines, play a significant role in inflammatory diseases by contributing to NO production. Elevated levels of IL-17A in the inflamed mucosa and sera of IBD patients correlate with Th17-associated cytokines like IL-6 and IL-23, as well as with increased NO production (223, 224). Enhanced phosphorylation of STAT3 (p-STAT3) in the colonic mucosa triggers RORγt expression, promoting Th17 cell development (224). The upregulation of nitric oxide synthase 2 (NOS2) and p-STAT3 levels in the gut mucosa correlates with the severity of inflammation in IBD, highlighting their role in disease progression. While NO has both cytotoxic and immunoregulatory functions, its overproduction, often supported by IFN-γ and IL-17, exacerbates chronic inflammation in IBD. Elevated NO levels in the gut mucosa stimulate the production of pro-inflammatory cytokines like IL-17 by Th17 cells, forming a feedback loop that perpetuates inflammation. This bidirectional interaction between NO and Th17 cells contributes to the pathogenesis and progression of inflammatory disorders in the gut.

Treg cells are predominantly found in the thymus, but evidence suggests the intestine is vital for inducible Treg (iTreg) cell differentiation (225, 226). Treg cells are present throughout the body, including peripheral tissues like the intestine. The majority of Treg cells are indeed generated in the thymus during T-cell development, however, the intestine plays a crucial role in the differentiation and maintenance of iTreg cells, which are generated locally in response to antigens encountered in the gut environment. The gut microenvironment, with its diverse array of antigens, commensal bacteria, and metabolites, provides stimuli that promote the differentiation of naïve T-cell into iTreg cells. Metabolites derived from dietary components and microbial fermentation, as well as signaling pathways like the aryl hydrocarbon receptor (AHR) pathway, contribute to the induction of iTreg cells in the intestine (141, 148, 149). TGF-β, abundant in gut epithelium, promotes Foxp3⁺ Treg development and identified as a master regulator of intestinal microbiota and immune cell interactions (227, 228) ( Figure 9 ). Imbalance between Tregs and Th1/Th17 cells correlates with severe intestinal inflammation (229, 230). NO, in conjunction with TCR activation, promotes the development and prolonged survival of Foxp3⁺ CD4⁺CD25⁺ Tregs from CD4⁺CD25⁻ T cells via p53, IL-2, and OX40 surviving signaling pathway (231). Moreover, research indicates that NO plays a pivotal role in FoxP3 regulation. Foxp3 is required for the adequate development and function of Tregs. Interestingly, experimental studies have shown that Foxp3 deficiency leads to a lack of CD4⁺CD25^hi Tregs, resulting in an inability to control the expansion of effector T-cells (232, 233). NO reduces FoxP3 expression and promotes Th1 cell differentiation by modulating TGF-β signaling (234). Studies show NO diminishes Foxp3 expression in MBP-primed T cells, while inhibiting iNOS or scavenging NO enhances Foxp3 expression (235). Both IL-6 and NO modulate TGF-β signaling, impacting T-cell differentiation toward Th17 or Th1 (235). Conversely, retinoic acid in the gut suppresses NO and IL-6, favoring Foxp3⁺ Treg over Th1/Th17 cells (234). This suggests a complex interplay between NO, TGF-β, and retinoic acid in regulating T-cell differentiation. Diet-derived metabolites like retinoic acid maintains gut barrier integrity and facilitates T cell homing into the gut (236, 237). Additionally, it enhances TGF-β-mediated induction of Foxp3⁺ Tregs by inhibiting Th17 development (238). Thus, NO exhibits dual roles, acting both as a cytotoxic agent and as an immunoregulator. Elevated NO levels are associated with chronic gut inflammation, driven by increased expression of pro-inflammatory cytokines like IFN-γ and IL-17, along with reduced levels of the anti-inflammatory cytokine TGF-β. These findings underscore the significant influence of NO on gut microbiota composition function, and T-cell regulation highlighting its potential role in shaping gut health and disease outcomes.

Future research in the field of gut redox and T-cell regulation holds significant promise for advancing our understanding of inflammatory and metabolic disorders and developing precision medicine approaches for their management. One key area for investigation is the elucidation of the complex interplay between gut redox balance, microbiota composition, and T-cell function. Understanding how alterations in gut redox homeostasis influence the composition and function of the microbiota, and in turn, impact T-cell responses, could provide insights into the pathogenesis of inflammatory and metabolic disorders. Moreover, identifying specific molecular pathways and signaling networks involved in mediating these interactions could reveal novel therapeutic targets for intervention. Challenges in this area include the need for comprehensive multi-omics approaches to capture the complexity of gut microbial communities and T-cell populations, as well as the integration of large-scale omics data with clinical phenotypes to identify predictive biomarkers of disease progression and treatment response. Cutting-edge technologies such as single-cell genomics and proteomics, coupled with advanced bioinformatic analyses, offer unprecedented opportunities to dissect the key molecular pathways underlying T-cell regulation in gut-related disorders. By leveraging these advanced tools, researchers can uncover novel molecular targets for precision medicine interventions aimed at modulating T-cell responses and restoring gut homeostasis in patients with inflammatory and metabolic disorders.